Novo Nordisk Cuts Jobs: Ozempic Market Shakeup

Ozempic maker Novo Nordisk slashes 9,000 jobs amid rising competition! Find out why the company is cutting 11% of its workforce, despite Ozempic's popularity, and how this drastic move aims to save $1.25 billion for future growth in diabetes and obesity treatments. Plus, discover how investors are reacting to the surprising announcement. Hosted on Acast. See acast.com/privacy for more information.